These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2867808)

  • 1. Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease.
    Beal MF; Marshall PE; Burd GD; Landis DM; Martin JB
    Brain Res; 1985 Dec; 361(1-2):135-45. PubMed ID: 2867808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
    Beal MF; Kowall NW; Swartz KJ; Ferrante RJ; Martin JB
    Synapse; 1989; 3(1):38-47. PubMed ID: 2563916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
    Beal MF; Ferrante RJ; Swartz KJ; Kowall NW
    J Neurosci; 1991 Jun; 11(6):1649-59. PubMed ID: 1710657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of Met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins.
    Ruzicka BB; Jhamandas K
    Brain Res; 1990 Dec; 536(1-2):227-39. PubMed ID: 2150770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lesions on somatostatin-like immunoreactivity in the rat striatum.
    Beal MF; Martin JB
    Brain Res; 1983 Apr; 266(1):67-73. PubMed ID: 6133592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum.
    Davies SW; Roberts PJ
    Neuroscience; 1988 Aug; 26(2):387-93. PubMed ID: 2971892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal ganglioside levels in the rat following kainic acid lesions: comparison with Huntington's disease.
    Higatsberger MR; Sperk G; Bernheimer H; Shannak KS; Hornykiewicz O
    Exp Brain Res; 1981; 44(1):93-6. PubMed ID: 6456150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin precursor in the rat striatum: changes after local injection of kainic acid.
    Sperk G; Widmann R
    J Neurochem; 1985 Nov; 45(5):1441-7. PubMed ID: 2864394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.
    Isacson O; Brundin P; Gage FH; Björklund A
    Neuroscience; 1985 Dec; 16(4):799-817. PubMed ID: 2936982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced density of striatal somatostatin receptors in Huntington's chorea.
    Palacios JM; Rigo M; Chinaglia G; Probst A
    Brain Res; 1990 Jul; 522(2):342-6. PubMed ID: 1977497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
    Marshall PE; Landis DM
    Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
    Beal MF; Kowall NW; Ellison DW; Mazurek MF; Swartz KJ; Martin JB
    Nature; 1986 May 8-14; 321(6066):168-71. PubMed ID: 2422561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease.
    Beal MF; Benoit R; Bird ED; Martin JB
    Neurosci Lett; 1985 May; 56(3):377-80. PubMed ID: 2862613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin content in the basal ganglia in Huntington's disease. The expression of cholecystokinin immunoreactivity in striatal grafts to ibotenic acid-lesioned rat striatum.
    Emson PC; Dawbarn D; Rossor MN; Rehfeld JF; Brundin P; Isacson O; Björklund A
    Ann N Y Acad Sci; 1985; 448():488-94. PubMed ID: 3161446
    [No Abstract]   [Full Text] [Related]  

  • 17. Depletion of striatal somatostatin by local cysteamine injection.
    Beal MF; Martin JB
    Brain Res; 1984 Aug; 308(2):319-24. PubMed ID: 6148124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
    Ferrante RJ; Kowall NW; Cipolloni PB; Storey E; Beal MF
    Exp Neurol; 1993 Jan; 119(1):46-71. PubMed ID: 8432351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
    Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
    Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of kainic acid on somatostatin, GABAergic and cholinergic neurons in the rat striatum.
    Araki M; McGeer PL; McGeer EG
    Neurosci Lett; 1985 Jan; 53(2):197-202. PubMed ID: 2858835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.